Advertisement

Inflammation

, Volume 39, Issue 1, pp 502–502 | Cite as

Retraction Note to: Different Aspects of Sartan + Calcium Antagonist Association Compared to the Single Therapy on Inflammation and Metabolic Parameters in Hypertensive Patients

  • Giuseppe DerosaEmail author
  • Arrigo F. G. Cicero
  • Anna Carbone
  • Fabrizio Querci
  • Elena Fogari
  • Angela D’Angelo
  • Pamela Maffioli
Retraction Note

Retraction to: Inflammation (2014) 37(1):154–162

DOI: 10.1007/s10753-013-9724-x

This article has been retracted at the request of the Editor-in-Chief.

The authors have published results from exactly the same clinical study and patient population in 6 separate articles, without referencing the publications in any of the later articles:

1. Derosa, G., Cicero, A.F.G., Carbone, A., Querci, F., Fogari, E., D’angelo, A., Maffioli, P. 2013. Olmesartan/amlodipine combination versus olmesartan or amlodipine monotherapies on blood pressure and insulin resistance in a sample of hypertensive patients. Clinical and Experimental Hypertension 35: 301–307. doi: 10.3109/10641963.2012.721841.

2. Derosa, G., Cicero, A.F.G., Carbone, A., Querci, F., Fogari, E., D’Angelo, A., Maffioli, P. 2013. Effects of an olmesartan/amlodipine fixed dose on blood pressure control, some adipocytokines and interleukins levels compared with olmesartan or amlodipine monotherapies. Journal of Clinical Pharmacy and Therapeutics 38: 48–55. doi: 10.1111/jcpt.12021.

3. Derosa, G., Cicero, A.F.G., Carbone, A., Querci, F., Fogari, E., D’Angelo, A., Maffioli, P. 2013. Variation of some inflammatory markers in hypertensive patients after 1 year of olmesartan/amlodipine single-pill combination compared with olmesartan or amlodipine monotherapies. Journal of the American Society of Hypertension 7: 32–39. doi: 10.1016/j.jash.2012.11.006.

4. Derosa, G., Cicero, A.F.G., Carbone, A., Querci, F., Fogari, E., D’Angelo, A., Maffioli, P. 2013. Evaluation of safety and efficacy of a fixed olmesartan/amlodipine combination therapy compared to single monotherapies. Expert Opinion on Drug Safety 12: 621–629. doi: 10.1517/14740338.2013.816674.

5. Derosa, G., Cicero, A.F.G., Carbone, A., Querci, F., Fogari, E., D’Angelo, A., Maffioli, P. 2014. Different aspects of sartan + calcium antagonist association compared to the single therapy on inflammation and metabolic parameters in hypertensive patients. Inflammation 37: 154–162. doi: 10.1007/s10753-013-9724-x.

6. Derosa, G., Cicero, A.F.G., Carbone, A., Querci, F., Fogari, E., D’Angelo, A., Maffioli, P. 2014. Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammation. European Journal of Pharmaceutical Sciences 51: 26–33. doi: 10.1016/j.ejps.2013.08.031.

In addition, the article in Inflammation contains results published especially in articles 2 and 6, which is the main reason for retraction of the article in Inflammation.

The publisher apologizes for the inconvenience caused.

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Giuseppe Derosa
    • 1
    • 2
    Email author
  • Arrigo F. G. Cicero
    • 3
  • Anna Carbone
    • 4
  • Fabrizio Querci
    • 5
  • Elena Fogari
    • 1
  • Angela D’Angelo
    • 1
  • Pamela Maffioli
    • 1
  1. 1.Department of Internal Medicine and TherapeuticsUniversity of Pavia, Fondazione IRCCS Policlinico S. MatteoPaviaItaly
  2. 2.Center for the Study of Endocrine-Metabolic Pathophysiology and Clinical ResearchUniversity of PaviaPaviaItaly
  3. 3.Aging and Kidney Diseases, “G. Descovich” Atherosclerosis Study CenterUniversity of BolognaBolognaItaly
  4. 4.Hospital Center of DiabetesLodiItaly
  5. 5.Ospedale Pesenti FenaroliBergamoItaly

Personalised recommendations